These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 30648519)
1. Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis. Rashid M; Shamshavali K; Chhabra M Curr Clin Pharmacol; 2019; 14(2):108-115. PubMed ID: 30648519 [TBL] [Abstract][Full Text] [Related]
2. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. Dijkman GA; Janknegt RA; De Reijke TM; Debruyne FM J Urol; 1997 Jul; 158(1):160-3. PubMed ID: 9186345 [TBL] [Abstract][Full Text] [Related]
4. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517 [TBL] [Abstract][Full Text] [Related]
5. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244 [TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Bertagna C; De Géry A; Hucher M; François JP; Zanirato J Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827 [TBL] [Abstract][Full Text] [Related]
8. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group. Janknegt RA Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials. Rashid M; Ramesh M; Shamshavali K; Dang A; Patel H; Undela K Rev Recent Clin Trials; 2020; 15(1):34-47. PubMed ID: 31692438 [TBL] [Abstract][Full Text] [Related]
10. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Nair B; Wilt T; MacDonald R; Rutks I Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665 [TBL] [Abstract][Full Text] [Related]
11. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Du Plessis DJ Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599 [TBL] [Abstract][Full Text] [Related]
12. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group. Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182 [TBL] [Abstract][Full Text] [Related]
13. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160 [TBL] [Abstract][Full Text] [Related]
14. Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ; Holdsworth MT Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470 [TBL] [Abstract][Full Text] [Related]
16. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies. Hucher M; de Gery A; Bertagna C Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510 [No Abstract] [Full Text] [Related]
17. Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study. Beland G Urology; 1991; 37(2 Suppl):25-9. PubMed ID: 1992600 [TBL] [Abstract][Full Text] [Related]